Fluvoxamine - FLCCC I-MASK+ Protocol for COVID-19 (May 2022)

Fluvoxamine and COVID-19

Fluvoxamine, developed 40 years ago as an antidepressant —sometimes known as Luvox—has been used mainly to treat obsessive-compulsive disorder (OCD), per the National Alliance on Mental Illness (NAMI). But now, researchers are taking a closer look at how the medication could be an important treatment to prevent patients who test positive for COVID-19 from getting seriously ill with the infection.
Fluvoxamine and COVID-19

FDA Turns Down Fluvoxamine Emergency Use Authorization Request (May 2022)

The Food and Drug Administration denied an emergency use authorization for fluvoxamine as a SARS-CoV-2 antiviral. Fluvoxamine was proposed as a possible antiviral in 2021 due to its mechanisms of action for treating obsessive-compulsive disorder. These same mechanisms were suspected to inhibit SARS-CoV-2, leading to four trials testing the efficacy of the drug.

In December 2021, Dr. David R Boulware requested an emergency use authorization for the outpatient treatment of adults testing positive for SARS-CoV-2 to prevent progression to severe symptoms based on early efficacy data from the fluvoxamine trials. The Food and Drug Administration denied his request, listing concerns such as insufficient data. 

“There are effective therapeutics that are available. But not everyone has access to them. Not everyone can tolerate them. Some people have contraindications,” Boulware argued in response to the FDA rejection. “And if you go elsewhere in the world, low- and middle-income countries, they have access to no therapeutics.”

Here we will discuss the FDA’s decision and reasoning.

The FDA’s main concern was the lack of conclusive evidence from four trials that were below emergency use authorization standards. The largest of the four trials, the TOGETHER trial, was a randomized, double-blind, placebo-controlled trial of high-risk patients in Brazil. The primary endpoints of the trial were (1) emergency room visits lasting greater than six hours and (2) hospitalization due to progression of Covid-19.

The FDA found that the success of the trial was fueled by the six-hour threshold, which they found to be arbitrary. A patient remaining in the emergency room for 5.9 hours after taking fluvoxamine was considered a positive data point, whereas 6.1 hours was considered a negative. In the FDA’s words, “there are uncertainties about…whether the 6-hour timepoint represents a clinically meaningful threshold.”

The other three trials were found to be inconclusive as well. The FDA noted that the STOP COVID trial had several damaging design flaws, including a lack of randomization, a small sample size, and only a single testing center. The STOP COVID 2 trial and the COVID-OUT trial both failed to demonstrate a positive efficacy for fluvoxamine and were terminated early for futility.

While the TOGETHER trial did achieve a positive efficacy based on its trial design, the FDA ultimately concluded that the four trials failed to provide sufficient data to conclude that fluvoxamine may be an effective treatment for nonhospitalized Covid-19 patients.

The FDA’s notice of emergency use rejection for fluvoxamine was concluded with currently available and approved treatments for Covid-19. These include Paxlovid, Remdesivir, Bebtelovimab, and convalescent plasma. We note that Molnupiravir is listed among these as well, but we discourage the use of this drug due to concerns about mutagenesis and cytotoxicity (R).

FLCCC (Front Line COVID-19 Critical Care) I-MASK Protocol

FLCCC Putting Patients First

The Front Line COVID-19 Critical Care (FLCCC) Alliance was initially formed as a working group during the early COVID-19 pandemic days in response to multiple early reports of COVID patients with an inexplicably high need for prolonged mechanical ventilation and an excessive death rate. 

Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the I-MASK+ protocol for prophylaxis and at home treatment of early stage COVID-19. 

Fluvoxamine was added to the latest FLCCC I-MASK+ early outpatient protocol as one of the second line agents for early treatment. Check out the summary of evidence on Fluvoxamine versus COVID-19 from c19fluvoxamine.com (constantly updated).

For updated prevention and early outpatient protocol  for COVID-19 positive, please check out FLCCC I-MASK+ protocol.

Alternate Treatments 

For a list of COVID-19 early treatment studies, check out c19early.com (constantly updated).
For post-covid or long covid syndrome, check out FLCCC I-Recover Post-COVID Protocol

Related: List of Doctors that will prescribe I-MASK+ protocol



Show more


Show more

Popular posts from this blog

12 Types of Zinc Supplementation and Absorption 2024

Fenbendazole vs Mebendazole: What is the Difference?

Fenbendazole Cancer Success Stories and Treatment Testimonials: Case Series (2024)

Lumbrokinase vs Nattokinase vs Serrapeptase: What's the Difference?

How to Detox Spike Protein After COVID - Dr Mercola

NAC vs NAD vs NR vs NMN? What are the Differences?

How Linoleic Acid Wrecks Your Health (2024) - Dr Mercola

FLCCC I-MASK+ Protocol for COVID-19

The Key to Reversing All Autoimmune Diseases - Dr Mercola

How to Get Ivermectin in the US: Pharmacies (2023)